Psoriasis on Face — Where It Appears, Why Treatment Is Harder, and What Helps

Facial psoriasis has preferred locations that reflect the underlying immune and skin characteristics of each site.

Hairline and forehead: the most common facial site. Plaques typically occur at the hairline, extending onto the forehead — visible as a red, scaly band. Often continuous with scalp psoriasis.

Eyebrows: well-defined red scaly plaques within the eyebrows. Often confused with seborrhoeic dermatitis — distinguishing: psoriasis has sharper borders, thicker scale; seborrhoeic dermatitis is more diffuse and greasier.

Nasolabial folds: the folds running from the nose to the corners of the mouth. Sebopsoriasis (overlap of psoriasis and seborrhoeic dermatitis) is common in this location.

Ears and periauricular: the external ear canal and behind the ear — often continuous with scalp psoriasis. Scaling in the ear canal causes itch and muffled hearing.

Periorbital area: around the eyes — delicate area requiring particular treatment caution. Eyelid involvement can affect vision and requires ophthalmology awareness.

Cheeks, chin, and lip border: less common. The vermilion border of the lips can show discrete scaling and redness.

Facial skin is significantly thinner than body skin, especially around the eyes. This creates a fundamental treatment challenge.

High-potency topical corticosteroids on the face: the same strong steroids effective on body plaques (clobetasol, betamethasone valerate) cause skin thinning, telangiectasia (visible blood vessels), perioral dermatitis, and steroid-induced rosacea on facial skin within weeks of continued use. These are not suitable for the face.

What is actually safe on the face: Mild corticosteroids — hydrocortisone 1% — safe for short-term face use, limited efficacy for established plaques. Tacrolimus (Protopic) and pimecrolimus (Elidel) — calcineurin inhibitors specifically designed for thin-skin sites, safe for face and eyelids, no skin thinning risk. Effective for facial psoriasis, especially periorbital. Available in India by prescription. Calcipotriol — reasonable safety profile on face, avoid periorbital area.

Near the eyes specifically: only tacrolimus (Protopic 0.03%) or pimecrolimus is appropriate near the eyelids. No corticosteroids, no calcipotriol periorbital. Ophthalmology review if eyelid psoriasis causes visual symptoms.

NB-UVB on the face: effective and safe. Eye protection essential during treatment.

Sebopsoriasis refers to the overlap between psoriasis and seborrhoeic dermatitis — occurring at sites rich in sebaceous glands: scalp, face (nasolabial folds, eyebrows, behind ears), and upper chest.

Why the overlap: both conditions share inflammatory pathways at sebaceous-rich sites. Malassezia yeast may trigger or worsen psoriasis at these specific locations through shared immune mechanisms.

Clinical appearance: sebopsoriasis has features of both — less sharply defined than classic psoriasis, greasier scale than typical psoriasis. Pure seborrhoeic dermatitis responds well to antifungal shampoos. Pure psoriasis does not. Sebopsoriasis responds partially to both.

Practical implication: for facial psoriasis at nasolabial folds and eyebrows, trial of ketoconazole cream alongside anti-psoriatic treatment is reasonable — targeting both components.

The distinction matters: if your facial psoriasis is predominantly at seborrhoeic sites and responds somewhat to antifungal — sebopsoriasis is likely. Classic plaques at non-seborrhoeic sites (forehead, cheeks) — pure psoriasis.

Facial psoriasis carries a disproportionate quality-of-life burden. The face is the primary social interface — it cannot be covered without obvious social signals.

Research consistently shows: patients with facial psoriasis score significantly lower on depression and anxiety scales than body-only psoriasis patients, even when the total body surface area affected is smaller. Visibility matters as much as extent.

Specific social situations in India: wedding photography, office environments, family gatherings, and marriage-age related pressure — all specifically impact patients with facial psoriasis in ways that body psoriasis does not.

Makeup and camouflage: medical-grade camouflage (Dermablend, Vichy Dermablend) is designed for skin conditions — higher coverage, non-comedogenic. Regular concealer is generally safe. Foundation over moisturised, non-scaling skin provides reasonable coverage. Avoid powder on psoriatic patches — it emphasises scale. Principle: moisturise thoroughly first, then apply coverage product.

Avoid: heavy foundation on active inflamed plaques (irritation risk), fragrant products near eyes, high-alcohol content products.

Cleansing: gentle, non-foaming cleanser (Cetaphil, Sebamed, Bioderma Sensibio) — once or twice daily. Foaming cleansers strip lipids and worsen dryness. Avoid exfoliants, scrubs, and harsh face washes.

Moisturiser: essential, twice daily minimum. Apply immediately after washing. Fragrance-free, non-comedogenic. Effective Indian options: Cetaphil moisturising cream, Bioderma Atoderm. In Indian summer, lighter gel formulations may be more comfortable.

Sun exposure on face: brief incidental sun (10-15 minutes) is generally beneficial for psoriasis. However, prolonged deliberate sun on active facial plaques is not recommended on thin facial skin. Sunscreen when going out — SPF 30 minimum, mineral sunscreens (zinc oxide, titanium dioxide) are better tolerated on psoriatic skin than chemical filters. Apply over moisturiser.

Shaving: for men with face psoriasis — electric razor reduces Koebner trauma compared to blade. Moisturising shaving gel, not foam. Shave along the grain. Avoid directly over active plaques when possible. Beard covering plaques gives some camouflage and UV protection — fragrance-free beard oil helps moisturise the underlying psoriatic skin.

Face-predominant psoriasis has specific constitutional significance in homoeopathic practice. The face is considered a highly expressive constitutional site — psoriasis expressing predominantly on the face, particularly with emotional stress as a clear trigger, points toward specific constitutional patterns.

The visibility-stress-flare cycle: patients with facial psoriasis describe a particularly vicious cycle — visible disease causes social anxiety and stress, stress triggers flares, flares worsen visibility and anxiety. This cycle is also the constitutional territory where homoeopathic treatment has specific relevance. The constitutional prescription addresses not just the skin but the constitutional response to stress and the emotional pattern that is part of the overall picture.

The thin-skin treatment limitation: the safest topical options for facial skin are less potent than what can be used on body skin. This creates a treatment gap specifically for facial psoriasis where topicals are maximally restricted. Constitutional homoeopathic treatment — systemic by nature — addresses the disease without the topical barrier.

Near the eyes: periorbital psoriasis is particularly restricted in terms of topical treatment (only tacrolimus). Constitutional treatment has no such restriction — there is no anatomical site exclusion.

What to expect: as constitutional treatment progresses, facial involvement often clears earlier than body involvement — an encouraging early signal. The face being a highly vascular, immune-active site, responds to systemic constitutional change. Many patients notice facial plaques thinning within 2-3 months of well-chosen constitutional treatment.

Dr. Shadab Khan — Akola, Maharashtra — WhatsApp 8983458889 — facial psoriasis including periorbital and severe cases, online India-wide.